TNYA

MKT CAP:$114M

Tenaya Therapeutics, Inc.

Market Cap

$114M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$0.70-$0.03 (-4.72%)

Apr 21, 2026

Company Details

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. ...

CEO

Faraz Ali

IPO Date

Jul 30, 2021

Website

www.tenayatherapeutics.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$91M

EPS (Diluted)

-$0.62

Free Cash Flow

-$69M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 13, 2026

PENDING

FY 2025

Mar 11, 2026

$0EPS -$0.59

Q4 2025

Mar 11, 2026

$0EPS -$0.12

Q3 2025

Nov 10, 2025

$0EPS -$0.12

Q2 2025

Aug 6, 2025

$0EPS -$0.14

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	-$1M	-$31M
Q2 22	$0	-$2M	-$29M
Q3 22	$0	-$3M	-$31M
Q4 22	$0	-$3M	-$35M
Q1 23	$0	-$3M	-$34M
Q2 23	$0	-$3M	-$35M
Q3 23	$0	-$3M	-$31M
Q4 23	$0	-$3M	-$31M
Q1 24	$0	-$2M	-$34M
Q2 24	$0	-$2M	-$31M
Q3 24	$0	$0	-$27M
Q4 24	$0	$0	-$25M
Q1 25	$0	$0	-$28M
Q2 25	$0	-$2M	-$24M
Q3 25	$0	-$2M	-$21M
Q4 25	$0	$4M	-$21M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$29M	-$37M
Q2 22	-$25M	-$33M
Q3 22	-$28M	-$32M
Q4 22	-$23M	-$23M
Q1 23	-$30M	-$31M
Q2 23	-$26M	-$26M
Q3 23	-$24M	-$24M
Q4 23	-$22M	-$22M
Q1 24	-$29M	-$29M
Q2 24	-$24M	-$24M
Q3 24	-$20M	-$20M
Q4 24	-$18M	-$19M
Q1 25	-$23M	-$23M
Q2 25	-$16M	-$16M
Q3 25	-$16M	-$16M
Q4 25	-$14M	-$14M

Capital Expenditures

Quarter	CapEx
Q1 22	$9M
Q2 22	$7M
Q3 22	$4M
Q4 22	$795.0K
Q1 23	$629.0K
Q2 23	$208.0K
Q3 23	$8.0K
Q4 23	$394.0K
Q1 24	$564.0K
Q2 24	$73.0K
Q3 24	$184.0K
Q4 24	$204.0K
Q1 25	$383.0K
Q2 25	$142.0K
Q3 25	$26.0K
Q4 25	$67.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+137.7%
Q2 22	—	+87.8%
Q3 22	—	+71.0%
Q4 22	—	+32.1%
Q1 23	—	+8.2%
Q2 23	—	+22.7%
Q3 23	—	-1.2%
Q4 23	—	-9.0%
Q1 24	—	+0.1%
Q2 24	—	-12.2%
Q3 24	—	-13.6%
Q4 24	—	-21.6%
Q1 25	—	-18.4%
Q2 25	—	-21.9%
Q3 25	—	-21.6%
Q4 25	—	-15.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$0	—
Q2 22	$0	—
Q3 22	$0	—
Q4 22	$3M	—
Q1 23	$4M	—
Q2 23	$4M	—
Q3 23	$4M	—
Q4 23	$0	—
Q1 24	$4M	—
Q2 24	$5M	—
Q3 24	$4M	—
Q4 24	$4M	—
Q1 25	$4M	—
Q2 25	$4M	—
Q3 25	$3M	—
Q4 25	$3M	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$24M	—	$6M
Q2 22	$21M	—	$6M
Q3 22	$24M	—	$5M
Q4 22	$26M	—	$6M
Q1 23	$26M	—	$5M
Q2 23	$26M	—	$6M
Q3 23	$23M	—	$5M
Q4 23	$23M	—	$6M
Q1 24	$25M	—	$7M
Q2 24	$23M	—	$6M
Q3 24	$20M	$6M	—
Q4 24	$19M	$6M	—
Q1 25	$21M	$6M	—
Q2 25	$17M	$7M	—
Q3 25	$15M	—	$4M
Q4 25	$15M	$6M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$26M	$184M	$210M
Q2 22	$31M	$150M	$181M
Q3 22	$34M	$115M	$149M
Q4 22	$95M	$91M	$187M
Q1 23	$73M	$75M	$148M
Q2 23	$76M	$57M	$133M
Q3 23	$82M	$40M	$122M
Q4 23	$46M	$59M	$105M
Q1 24	$59M	$63M	$122M
Q2 24	$58M	$41M	$99M
Q3 24	$8M	$71M	$79M
Q4 24	$4M	$57M	$61M
Q1 25	$54M	$34M	$88M
Q2 25	$63M	$9M	$72M
Q3 25	$56M	$0	$56M
Q4 25	$101M	$0	$101M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	41M	+0.0%	+51.7%
Q2 22	41M	+0.1%	+10.7%
Q3 22	41M	+0.1%	+53.8%
Q4 22	55M	+33.6%	+33.9%
Q1 23	73M	+32.3%	+77.1%
Q2 23	73M	+0.4%	+77.7%
Q3 23	74M	+0.7%	+78.7%
Q4 23	68M	-7.6%	+23.7%
Q1 24	81M	+18.5%	+10.8%
Q2 24	86M	+5.8%	+16.8%
Q3 24	86M	+0.5%	+16.6%
Q4 24	86M	+0.3%	+26.5%
Q1 25	110M	+27.2%	+35.7%
Q2 25	163M	+48.2%	+89.9%
Q3 25	163M	+0.3%	+89.6%
Q4 25	153M	-6.4%	+77.0%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	106
Q2 22	$0	106
Q3 22	$0	106
Q4 22	$0	141
Q1 23	$0	141
Q2 23	$0	141
Q3 23	$0	141
Q4 23	$0	140
Q1 24	$0	140
Q2 24	$0	140
Q3 24	$0	140
Q4 24	$0	97
Q1 25	$0	97
Q2 25	$0	97
Q3 25	$0	97
Q4 25	$0	120K

Revenue / Employee